http://www.medhelp.org/user_journals/show/1739543 Medical communities and forums staffed by doctors from leading medical centers. Over 325 forums and communities providing medical information and medical help. en AbbVie reported results of a trial involving a 12 week regimen of 3 drugs combined with RBV trials (9 Advocate1955 Sun, 28 Apr 2013 14:09:52 -0500 http://www.medhelp.org/user_journals/show/751088/EASL-2013--International-Liver-Conference--AbbVie http://www.medhelp.org/user_journals/show/751088/EASL-2013--International-Liver-Conference--AbbVie Janssen R & D (Ireland) reported results of two Phase 3 trials, G1 & G2, treatment naive, simeprevir. Advocate1955 Sun, 28 Apr 2013 14:04:00 -0500 http://www.medhelp.org/user_journals/show/751085/EASL-2013--International-Liver-Conference--Janssen http://www.medhelp.org/user_journals/show/751085/EASL-2013--International-Liver-Conference--Janssen Boehringer Ingelheim reported results of one Phase 3 trial, STARTVerso at the EASL 2013 International Advocate1955 Sun, 28 Apr 2013 13:59:48 -0500 http://www.medhelp.org/user_journals/show/751083/EASL-2013--International-Liver-Conference--Boehringer-Ingelheim http://www.medhelp.org/user_journals/show/751083/EASL-2013--International-Liver-Conference--Boehringer-Ingelheim Gilead reported results on four phase 3 trials with sofosbuvir at EASL 2013, International Liver Conf Advocate1955 Sun, 28 Apr 2013 13:54:50 -0500 http://www.medhelp.org/user_journals/show/751082/EASL-2013--International-Liver-Conference--Gilead http://www.medhelp.org/user_journals/show/751082/EASL-2013--International-Liver-Conference--Gilead Copyman, another member of this forum, posted this link to a Hep C Survival Guide a couple of days ag Advocate1955 Wed, 26 Dec 2012 12:01:42 -0600 http://www.medhelp.org/user_journals/show/634676/Link-to-Hep-C-Survival-Guide http://www.medhelp.org/user_journals/show/634676/Link-to-Hep-C-Survival-Guide Thank you to mikesimon for sharing this article. I am posting it in my journal for reference. Advoc Advocate1955 Wed, 19 Dec 2012 07:45:31 -0600 http://www.medhelp.org/user_journals/show/628735/Regular-marijuana-use-increases-risk-of-Hep-C-related-liver-damage http://www.medhelp.org/user_journals/show/628735/Regular-marijuana-use-increases-risk-of-Hep-C-related-liver-damage Here is a copy of a list that Orphaned Hawk posted in her journal and a list that Hector SF posted Advocate1955 Wed, 05 Dec 2012 07:55:20 -0600 http://www.medhelp.org/user_journals/show/615811/Preparing-for-first-appointment-with-hepatologist http://www.medhelp.org/user_journals/show/615811/Preparing-for-first-appointment-with-hepatologist Saw hepatologist last week. News is good. Liver is compensated, no sign of cancer, labs good. CT Advocate1955 Sat, 01 Dec 2012 15:03:56 -0600 http://www.medhelp.org/user_journals/show/610936/Follow-up-with-Hepatologist--Nov--2012 http://www.medhelp.org/user_journals/show/610936/Follow-up-with-Hepatologist--Nov--2012 Bristol-Myers Squibb Company (BMS) announced yesterday at the Liver Meeting in Boston, Nov. 2012, tha Advocate1955 Mon, 12 Nov 2012 09:00:14 -0600 http://www.medhelp.org/user_journals/show/588318/Bristol-Myers-Squibb-Co--Phase-2-Data--Asunaprevir--Daclatasvir--up-to-78-SVR-rate-in-G1b-previous-null-responders http://www.medhelp.org/user_journals/show/588318/Bristol-Myers-Squibb-Co--Phase-2-Data--Asunaprevir--Daclatasvir--up-to-78-SVR-rate-in-G1b-previous-null-responders This information has already been posted on the Hep C forum, but I wanted to post it in my journals f Advocate1955 Sun, 11 Nov 2012 12:18:00 -0600 http://www.medhelp.org/user_journals/show/587516/Abbotts-triple-DAA-regimen-plus-Ribavirin--12-weeks--high-rates-of-SVR-in-both-treatment-naive-and-null-responders http://www.medhelp.org/user_journals/show/587516/Abbotts-triple-DAA-regimen-plus-Ribavirin--12-weeks--high-rates-of-SVR-in-both-treatment-naive-and-null-responders Boehringer Ingelheim (BI) announced that faldaprevir (BI201335) and BI207127 combined with Ribavirin Advocate1955 Sun, 11 Nov 2012 11:36:00 -0600 http://www.medhelp.org/user_journals/show/587498/Boehringer-Ingelheims-faldaprevir-BI201335--up-to-85-SVR-in-treatment-naive http://www.medhelp.org/user_journals/show/587498/Boehringer-Ingelheims-faldaprevir-BI201335--up-to-85-SVR-in-treatment-naive Merck announced that 96% of trial patients achieved SVR12 with it's protease inhibitor (MK-5172) comb Advocate1955 Sun, 11 Nov 2012 11:09:29 -0600 http://www.medhelp.org/user_journals/show/587495/Mercks-MK-5172-Phase-2-study--protease-inhibitor--96-SVR12 http://www.medhelp.org/user_journals/show/587495/Mercks-MK-5172-Phase-2-study--protease-inhibitor--96-SVR12 This has already been posted by Orphaned Hawk on the Hep C forum, but I thought it might be a good id Advocate1955 Sun, 11 Nov 2012 11:00:53 -0600 http://www.medhelp.org/user_journals/show/587492/Gileads-Sofosbuvir-GS-7977--100-SVR4-in-treatment-naive-G1s http://www.medhelp.org/user_journals/show/587492/Gileads-Sofosbuvir-GS-7977--100-SVR4-in-treatment-naive-G1s Vertex presented information at the AASLD conference in Boston in Nov., 2012. According to this arti Advocate1955 Sun, 11 Nov 2012 10:53:12 -0600 http://www.medhelp.org/user_journals/show/587490/VX-135-Vertexs-oral-nucleotide-shows-rapid-reduction-of-HCV-RNA http://www.medhelp.org/user_journals/show/587490/VX-135-Vertexs-oral-nucleotide-shows-rapid-reduction-of-HCV-RNA Janssen presented information on it's protease inhibitor simeprever (TMC435) at the AASLD conference Advocate1955 Sun, 11 Nov 2012 10:45:03 -0600 http://www.medhelp.org/user_journals/show/587487/Simeprever-TMC435--AASLD--Nov-2012 http://www.medhelp.org/user_journals/show/587487/Simeprever-TMC435--AASLD--Nov-2012 This article was posted on 4/19/12 on HCV New Drug Research and can be viewed at http://hepatitiscnew Advocate1955 Sun, 22 Apr 2012 13:20:27 -0500 http://www.medhelp.org/user_journals/show/353717/EASL-ABT-450-r-plus-ABT-333-plus-Riba--SVR12-rates http://www.medhelp.org/user_journals/show/353717/EASL-ABT-450-r-plus-ABT-333-plus-Riba--SVR12-rates This article was posted on HCV New Drug Research on 4/19/12 and can be viewed at: http://hepatitiscn Advocate1955 Sun, 22 Apr 2012 13:04:58 -0500 http://www.medhelp.org/user_journals/show/353715/EASL-GS-7977-combined-with-Interferon--Ribavirin--12-wk-treatment--94-SVR-rate--treatment-naive--genotype-1 http://www.medhelp.org/user_journals/show/353715/EASL-GS-7977-combined-with-Interferon--Ribavirin--12-wk-treatment--94-SVR-rate--treatment-naive--genotype-1 The article below was posted on HCV New Drug Research on 4/19/12, and can be found at http://hepatiti Advocate1955 Sun, 22 Apr 2012 12:13:09 -0500 http://www.medhelp.org/user_journals/show/353706/EASL-TMC435-combined-with-Interferon-and-Ribavirin--61-80-SVR--previous-treatment-failures--null-responders--with-Cirrhosis http://www.medhelp.org/user_journals/show/353706/EASL-TMC435-combined-with-Interferon-and-Ribavirin--61-80-SVR--previous-treatment-failures--null-responders--with-Cirrhosis This article about Daclatasvir (BMS-790052) and Asunaprevir (BMS-650032) was posted on HCV New Drug R Advocate1955 Sun, 22 Apr 2012 11:54:57 -0500 http://www.medhelp.org/user_journals/show/353703/EASL-Daclatasvir--Asunaprevir--77-difficult-to-treat--HCV-g1b--achieved-SVR-in-trials http://www.medhelp.org/user_journals/show/353703/EASL-Daclatasvir--Asunaprevir--77-difficult-to-treat--HCV-g1b--achieved-SVR-in-trials This article was posted on HCV New Drug Research on 4/20/12, and can be found at: http://hepatitiscn Advocate1955 Sun, 22 Apr 2012 11:41:44 -0500 http://www.medhelp.org/user_journals/show/353700/EASL-BI-201335--BI-257127--Ribavirin--71-SVR-rate-with-trial-participants-with-HCV-G1-and-Cirrhosis http://www.medhelp.org/user_journals/show/353700/EASL-BI-201335--BI-257127--Ribavirin--71-SVR-rate-with-trial-participants-with-HCV-G1-and-Cirrhosis